- Reuters•12 hours ago
Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year. The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Vytorin, while Teva Pharmaceutical Industries Ltd launched its generic version of the drug in the United States. Impax said it will immediately start commercialization for its generic version of Vytorin.
- Reuters•13 hours ago
The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug Vytorin, the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales. Vytorin is a combination product that includes the drugs ezetimibe and simvastatin, sold under the brand names Zocor and Zetia. Zetia lost patent protection on Tuesday.
- Zacks•18 hours ago
Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.
MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||62.43 - 62.88|
|52 Week Range||53.06 - 66.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||44.47|
|Dividend & Yield||1.88 (2.99%)|
|1y Target Est||N/A|